Cipla sees 3 big exits from top management of India business, including CEO Nikhil Chopra
Pharma major Cipla has seen three exits of the top India leadership team including the head of the company’s unit in the country.
- Nikhil Chopra, Executive Vice-President, and CEO of India business, who was given the charge last year, has resigned. He has been a Cipla veteran with over 24 years in the company and has been instrumental in integrating the generics business.
- Nikhil Lalwani, Head of India Prescriptions Business, reporting directly to CEO Nikhil Chopra has also resigned. He was early responsible for Cipla’s business in the United States.
- Kunal Khanna, Cluster Head of Chronic and Emerging Business Development, and the portfolio has also moved out.
According to media reports, Nikhil Chopra will be leading the India business until September 2020 for a seamless transition. Chopra’s successor is yet to be announced and in the interim, all direct reports of Nikhil Chopra will be reporting to company CEO Umang Vohra.
“They have served significant tenures in Cipla; we deeply value their contribution, respect their professional aspirations, and wish them all the best,” Cipla said in a statement.
The company’s rich legacy of care and a strong sense of purpose rooted in a culture of meritocracy and high-performance standards have made Cipla an employer of choice for several industry leaders, it added.
“Cipla is a professionally run organisation with robust talent management and succession development processes.
“Our business momentum continues to be on strong footing and we are backed by a solid workforce of 23,000 employees who are driving Cipla in its next growth phase,” the statement said.
Chopra joined the company in 1996 and has served in various leadership positions across India. The company, however, did not share the reasons for the exits.